Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023

VANCOUVER, British Columbia, May 03, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
May 02, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first...
April 24, 2023 08:00 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting

Oral presentation by Dr. Jacqueline French to outline sustained monthly reduction in focal onset seizures during open-label extension of X-TOLE study Poster to present the trial design for Phase 3...
April 21, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

BURNABY, British Columbia, April 21, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company...
April 18, 2023 08:15 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

BURNABY, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
March 22, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days

BURNABY, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
March 01, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major...
February 22, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

BURNABY, British Columbia, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth...
February 08, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

BURNABY, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at...
January 09, 2023 08:00 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023

XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong financial position expected to fully support XEN1101...